Literature DB >> 19110652

Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan.

Shuichi Miyakawa1, Shin Ishihara, Akihiko Horiguchi, Tadahiro Takada, Masaru Miyazaki, Takukazu Nagakawa.   

Abstract

BACKGROUND/
PURPOSE: The results from the Japanese Biliary Tract Cancer Statistics Registry from 1988 to 1998 were reported in 2002. In the present study, we report here selectively summarized data as an overview of the 2006 follow-up survey of the registered cases from 1998 to 2004 for information bearing on problems with the treatment of cancer of the biliary tract.
METHODS: A total of 5,584 patients were registered from 1998 to 2004. The site of cancer was the bile duct in 2,732 patients, the gallbladder in 2,067, and the papilla of Vater in 785. Those cases were analyzed with regard to patient survival according to the extent of tumor invasion (pT), the extent of lymph node metastasis (pN) and the stage.
RESULTS: The five-year survival rate after surgical resection was 33.1% for bile duct cancer, 41.6% for gallbladder cancer, and 52.8% for cancer of the papilla of Vater. For hilar or superior bile duct cancer, the 5-year survival rate was lower with an increase in the pT, pN and f stage, except pT3 vs. pT4, pN1 vs. pN2 and stage III vs. stage IVa. For middle or distal bile duct cancer, the 5-year survival rate was lower with increase in pT, pN and f stage, except pT2 vs. pT3, pN2 vs. pN3, stage II vs. stage III and stage III vs. stage IVa. For gallbladder cancer, the 5-year survival rate was lower with increase in pT, pN and f stage. For cancer of the papilla of Vater, the 5-year survival rate was lower with increase in pT, pN and f stage, except pT1 vs. pT2, pN1 vs. pN2, and stage III vs. stage IVa.
CONCLUSIONS: In the present study, the outcomes of surgical treatment were better than that of the previous report from Japan and foreign countries. The pT, pN and stage of gallbladder cancer are well defined. However, there were no significant differences in some groups of those of bile duct cancer and cancer of the papilla of Vater.

Entities:  

Mesh:

Year:  2008        PMID: 19110652     DOI: 10.1007/s00534-008-0015-0

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  69 in total

1.  Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study.

Authors:  Junichi Shindoh; Xabier de Aretxabala; Thomas A Aloia; Juan Carlos Roa; Ivan Roa; Giuseppe Zimmitti; Milind Javle; Claudius Conrad; Dipen M Maru; Taku Aoki; Luca Vigano; Dario Ribero; Norihiro Kokudo; Lorenzo Capussotti; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2015-04       Impact factor: 12.969

2.  Prognostic factors of patients with advanced gallbladder carcinoma following aggressive surgical resection.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Akira Nakashima; Naru Kondo; Ryutaro Sakabe; Hironori Kobayashi; Taijiro Sueda
Journal:  J Gastrointest Surg       Date:  2011-03-10       Impact factor: 3.452

3.  A phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable biliary tract cancer.

Authors:  Tsuyoshi Hayashi; Hirotoshi Ishiwatari; Makoto Yoshida; Tsutomu Sato; Koji Miyanishi; Yasushi Sato; Masayoshi Kobune; Rishu Takimoto; Tomoko Sonoda; Junji Kato
Journal:  Int J Clin Oncol       Date:  2011-09-21       Impact factor: 3.402

4.  Glasgow Prognostic Score predicts poor prognosis among advanced biliary tract cancer patients with good performance status.

Authors:  Toshikazu Moriwaki; Kazunori Ishige; Masahiro Araki; Shigemasa Yoshida; Masaaki Nishi; Mikio Sato; Takeshi Yamada; Yoshiyuki Yamamoto; Mitsuharu Ozeki; Hiroyasu Ishida; Takashi Yamaguchi; Kenji Matsuda; Tetsuya Murashita; Masato Abei; Ichinosuke Hyodo
Journal:  Med Oncol       Date:  2014-10-16       Impact factor: 3.064

5.  Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer.

Authors:  Takashi Sasaki; Hiroyuki Isayama; Yousuke Nakai; Yukiko Ito; Ichiro Yasuda; Nobuo Toda; Hiroshi Yagioka; Saburo Matsubara; Keiji Hanada; Hiroyuki Maguchi; Hideki Kamada; Osamu Hasebe; Tsuyoshi Mukai; Yoshihiro Okabe; Iruru Maetani; Kazuhiko Koike
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

6.  Prognostic role of neutrophil-to-lymphocyte ratio (NLR) in patients with operable ampullary carcinoma.

Authors:  Nebi Serkan Demirci; Gokmen Umut Erdem
Journal:  Bosn J Basic Med Sci       Date:  2018-08-01       Impact factor: 3.363

7.  Is it possible to define early distal cholangiocarcinoma?

Authors:  Fumihiko Miura; Keiji Sano; Hodaka Amano; Naoyuki Toyota; Keita Wada; Takuo Tokairin; Fukuo Kondo; Koichi Hayano; Hisahiro Matsubara; Tadahiro Takada
Journal:  Langenbecks Arch Surg       Date:  2015-10-30       Impact factor: 3.445

8.  Impact of Secreted Protein Acidic and Rich in Cysteine (SPARC) Expression on Prognosis After Surgical Resection for Biliary Carcinoma.

Authors:  Kazuhiro Toyota; Yoshiaki Murakami; Naru Kondo; Kenichiro Uemura; Naoya Nakagawa; Shinya Takahashi; Taijiro Sueda
Journal:  J Gastrointest Surg       Date:  2017-03-24       Impact factor: 3.452

9.  Incidental Gallbladder Cancer on Cholecystectomy: Strategy for Re-resection of Presumed Benign Diseases from a Retrospective Multicenter Study by the Yokohama Clinical Oncology Group.

Authors:  Ryusei Matsuyama; Kenichi Matsuo; Ryutaro Mori; Mitsutaka Sugita; Naotaka Yamaguchi; Toru Kubota; Kunio Kameda; Yasuhisa Mochizuki; Ryo Takagawa; Toshiaki Kadokura; Goro Matsuda; Noriyuki Kamiya; Itaru Endo
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

10.  Immunohistochemical Examination of a Resected Advanced Hilar Cholangiocarcinoma Arising in a 29-Year-Old Male without Primary Sclerosing Cholangitis.

Authors:  Taketoshi Suehiro; Takashi Matsumata; Tomohiro Iguchi; Kensaku Sanefuji; Ken-Ichi Nomoto; Akinobu Taketomi; Ken Shirabe; Yoshihiko Maehara
Journal:  Case Rep Gastroenterol       Date:  2010-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.